Small Molecule · CPL500036

Alofropodect

Phase 2Celon Pharma S.A. (CLN)

Alofropodect (CPL'36, CPL500036) is an oral, once-daily, second-generation phosphodiesterase 10A (PDE10A) inhibitor discovered and developed by Celon Pharma S.A. (Poland). PDE10A is expressed almost exclusively in striatal medium spiny neurons; Celon describes the compound as a potent, fast-dissociating PDE10A inhibitor that modulates dopaminergic and glutamatergic striatal signalling without blocking D2 receptors. Preclinically it inhibited PDE10A with an IC50 of 1 nM, was selective in a 44-target binding panel, was orally bioavailable and brain-penetrant, and did not raise prolactin or glucose in rats. In a 189-patient Phase 2 trial in acute schizophrenia (NCT05278156), 20 mg and 40 mg once daily both met the primary endpoint (PANSS positive subscale at week 4) versus placebo, and a 105-patient Phase 2 trial in levodopa-induced dyskinesia in Parkinson's disease (NCT05297201) met its UDysRS primary endpoint. After a Type B meeting the FDA endorsed a Phase 3 schizophrenia program (two 4-week acute trials plus a 12-month open-label extension), which Celon expects to start in 2026.

Also known as: CPL500036, CPL'36, CPL-500036, CPL 500036, CPL36, alofropodect, 1829530-11-1, 5,8-dimethyl-2-(2-phenylimidazo[1,2-a]pyrimidin-7-yl)-[1,2,4]triazolo[1,5-a]pyrazine

Key facts

Modality
Small molecule
Chemical class
triazolopyrazine, imidazopyrimidine
Chemistry
Achiral
Mechanism
PDE10A inhibitor
Highest phase
Phase 2
Lead indication
Schizophrenia
Developer
Celon Pharma S.A. (CLN)
Trials
3 tracked · 32 sites

Mechanism of action#

Potent, selective inhibitor of phosphodiesterase 10A (PDE10A), a dual cAMP/cGMP phosphodiesterase expressed almost exclusively in striatal medium spiny neurons. Inhibiting PDE10A raises cyclic-nucleotide signalling in both the D1 (direct) and D2 (indirect) pathway neurons; Celon describes alofropodect as a second-generation, fast-dissociating ('fast-off') inhibitor with preferential modulation of D2- over D1-mediated striatal pathways, which it proposes as the reason it succeeded where earlier PDE10A inhibitors (e.g. TAK-063/balipodect, MK-8189/elpipodect) did not. In vitro it inhibited PDE10A with an IC50 of 1 nM and, in a 44-target radioligand panel, interacted only with the muscarinic M2 receptor (negative allosteric modulator, IC50 9.2 uM). It inhibited the hERG tail current at IC25 3.2 uM without cardiovascular effects in 3D cardiac spheroids or dog telemetry, elicited catalepsy in rats at 0.6 mg/kg, and did not cause hyperprolactinaemia or hyperglycaemia at doses up to 3 mg/kg.

TargetActionAffinity
PDE10AprimaryPDE10AInhibitorIC50 1 nMⓘ

Formulations#

FormulationRouteRegimenPharmacokinetics
Alofropodect oral capsule (20 mg / 40 mg once daily)
20 mg or 40 mg PO once daily in the morning for 28 days in both Phase 2 trials (schizophrenia NCT05278156; levodopa-induced dyskinesia NCT05297201). Phase 1 (NCT03873324): single ascending doses in 7 cohorts and 14-day multiple ascending doses in 4 cohorts, with placebo capsules; the CNS Drugs paper reports safety and dose-dependent exposure up to 100 mg daily in Phase 1.
OralOnce daily—

Development timeline#

2020202220242026TodayPhase 116 Sept 2019 — phase change — First-in-human single and multiple ascending dose study in healthy volunteers (NCT03873324, 56 participants, Poland) completed; started 2018-12-20.Phase 231 Jul 2026 — readout (met) — Peer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg.8 Oct 2025 — phase change — Celon announced positive FDA feedback from a Type B meeting: existing preclinical data are sufficient to start pivotal studies; the FDA endorsed a Phase 3 program of two 28-day acute trials plus a 12-month open-label extension. Celon expects to start pivotal studies in 2026. Program kept at phase_2 until a Phase 3 trial starts.8 Oct 2025 — FDA regulatory meeting / outcome — FDA Type B meeting clears the path to Phase 3 for CPL'36 in schizophrenia4 Mar 2025 — readout (met) — Phase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001).27 Jan 2025 — phase change — NCT05297201 completed (primary completion 2025-01-13, study completion 2025-01-27) with 105 participants enrolled.27 Jan 2025 — Trial (portion) completed — Phase 2 LID study of CPL500036 (NCT05297201) completed5 Jul 2024 — readout (met) — Phase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001).19 Jun 2024 — phase change — NCT05278156 completed (primary completion 2024-06-05, study completion 2024-06-19), 189 participants enrolled.19 Jun 2024 — Trial (portion) completed — Phase 2 schizophrenia study of CPL500036 (NCT05278156) completed2 Nov 2021 — phase change — Phase 2 randomised, placebo-controlled study NCT05297201 in levodopa-induced dyskinesia started (CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in UDysRS total score at Week 4).19 May 2021 — phase change — Phase 2 randomised, double-blind, placebo-controlled study NCT05278156 in acute schizophrenia started (189 patients; CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in PANSS positive subscale at Day 28).
Phase change Readout Event UpcomingHover a marker for details.
Phase 2May 2021 – Jul 2026
  1. metPeer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg.Schizophrenia↗
  2. Celon announced positive FDA feedback from a Type B meeting: existing preclinical data are sufficient to start pivotal studies; the FDA endorsed a Phase 3 program of two 28-day acute trials plus a 12-month open-label extension. Celon expects to start pivotal studies in 2026. Program kept at phase_2 until a Phase 3 trial starts.Schizophrenia↗
  3. FDA regulatory meeting / outcomeFDA Type B meeting clears the path to Phase 3 for CPL'36 in schizophreniaSchizophrenia↗
  4. metPhase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001).Levodopa-induced dyskinesia in Parkinson's disease↗
  5. NCT05297201 completed (primary completion 2025-01-13, study completion 2025-01-27) with 105 participants enrolled.Levodopa-induced dyskinesia in Parkinson's disease
  6. Trial (portion) completedPhase 2 LID study of CPL500036 (NCT05297201) completedLevodopa-induced dyskinesia in Parkinson's disease
  7. metPhase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001).Schizophrenia↗
  8. NCT05278156 completed (primary completion 2024-06-05, study completion 2024-06-19), 189 participants enrolled.Schizophrenia
  9. Trial (portion) completedPhase 2 schizophrenia study of CPL500036 (NCT05278156) completedSchizophrenia
  10. Phase 2 randomised, placebo-controlled study NCT05297201 in levodopa-induced dyskinesia started (CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in UDysRS total score at Week 4).Levodopa-induced dyskinesia in Parkinson's disease
  11. Phase 2 randomised, double-blind, placebo-controlled study NCT05278156 in acute schizophrenia started (189 patients; CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in PANSS positive subscale at Day 28).Schizophrenia
Phase 1Sept 2019
  1. First-in-human single and multiple ascending dose study in healthy volunteers (NCT03873324, 56 participants, Poland) completed; started 2018-12-20.Schizophrenia

Alofropodect for Schizophrenia#

Phase 2ActiveSchizophrenia indication →

Alofropodect (CPL'36), Celon Pharma's once-daily PDE10A inhibitor, for schizophrenia - the lead indication. In a Phase 2 trial of 189 patients with acute schizophrenia, CPL'36 20 mg and 40 mg once daily for 4 weeks significantly improved the PANSS positive subscale (primary endpoint) versus placebo by 3.7 points (Cohen's d 0.73) and 6.3 points (d 1.38), and the PANSS total score by 9.7 and 16.4 points (both p<0.001), with early signs of cognitive benefit at 40 mg. After a Type B meeting the FDA said the existing preclinical data are sufficient to start pivotal studies and agreed 'treatment of schizophrenia' is the appropriate indication; the planned Phase 3 program is two 28-day randomized, double-blind trials in acute schizophrenia plus a 12-month open-label extension, with drug-drug interaction, QTc and mass-balance studies run alongside. Celon expects to start the pivotal studies in 2026 and is seeking a global partner.

Readouts

  • 2026-07-31ReportedFull resultsmetNCT05278156

    Peer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg. ↗

  • 2024-07-05ReportedTopline datametNCT05278156

    Phase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001). ↗

Alofropodect for Levodopa-induced dyskinesia in Parkinson's disease#

Phase 2ActiveLevodopa-induced dyskinesia in Parkinson's disease indication →

Alofropodect (CPL'36), Celon Pharma's once-daily PDE10A inhibitor, for levodopa-induced dyskinesia (LID) in Parkinson's disease - the second indication. A multinational Phase 2 trial randomised 105 adults with moderate-to-severe LID 1:1:1 to 20 mg, 40 mg or placebo once daily for 4 weeks; both doses met the primary endpoint, improving the UDysRS total score versus placebo by 12.30 units (20 mg, p<0.001, Cohen's d 0.90) and 13.58 units (40 mg, p<0.001, d 1.00), with the UDysRS objective subscale improving from Day 7. The most common adverse event was mild-to-moderate somnolence; treatment-related discontinuations were 2.9% placebo, 11.1% 20 mg and 8.6% 40 mg, and one serious adverse event (moderate atrial fibrillation) occurred at 40 mg.

Readouts

  • 2025-03-04ReportedTopline datametNCT05297201

    Phase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001). ↗

Clinical trials#

NCT0529720103PDE2020Phase 2Completedn=105

Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia

Started Nov 2021· Primary completion Jan 2025· 16 sites across 2 countries

UkrainePoland

NCT0527815602PDE2019Phase 2Completedn=189

Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

Started May 2021· Primary completion Jun 2024· 16 sites across 3 countries

UkraineHungaryPoland

NCT0387332401PDE2018Phase 1Completedn=56

Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers

Started Dec 2018· Primary completion Sept 2019

Conference coverage#

CPL500036 appears in 1 CNS Pulse conference abstract:

Sources#

  1. Celon Pharma publikuje dane dla II fazy klinicznej czasteczki CPL'36 we wskazaniu schizofrenia (2024-07-05) — Strefa Inwestorow
  2. FDA Clears Celon Pharma's Schizophrenia Drug for Phase 3 Trial (2025-10-08) — Celon Pharma S.A. (via GlobeNewswire / BioSpace)
  3. Matloka M, et al. A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. Front Pharmacol. 2022;13:999685 — Frontiers in Pharmacology / PubMed
  4. NCT03873324 (01PDE2018) - Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers — ClinicalTrials.gov (U.S. National Library of Medicine)
  5. NCT05278156 (02PDE2019) - Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia — ClinicalTrials.gov (U.S. National Library of Medicine)
  6. NCT05297201 (03PDE2020) - Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia — ClinicalTrials.gov (U.S. National Library of Medicine)
  7. Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease (Celon Pharma, 2025-03-04, repost) — Celon Pharma S.A. (reposted by santelog.com)
  8. Wieczorek M, et al. CNS Drugs 2026 - full text (PK, adverse events, funding) — CNS Drugs (Springer) via PubMed Central
  9. Wieczorek M, et al. PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia. CNS Drugs. 2026;40(9):1295-1305 — CNS Drugs (Springer) / PubMed